OBJECTIVE: To determine the prevalence of JC virus (JCV) reactivation and JCV-specific cellular immune response during prolonged natalizumab treatment for multiple sclerosis (MS). METHODS: We enrolled 43 JCV-seropositive MS patients, including 32 on natalizumab monotherapy >18 months, 6 on interferon β-1a monotherapy >36 months, and 5 untreated controls. We performed quantitative real-time polymerase chain reaction in cerebrospinal fluid (CSF), blood, and urine for JCV DNA, and we determined JCV-specific T-cell responses using enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine staining (ICS) assays, ex vivo and after in vitro stimulation with JCV peptides. RESULTS: JCV DNA was detected in the CSF of 2 of 27 (7.4%) natalizumab-treated MS patients who had no symptoms or magnetic resonance imaging-detected lesions consistent with progressive multifocal leukoencephalopathy. JCV DNA was detected in blood of 12 of 43 (27.9%) and in urine of 11 of 43 (25.6%) subjects without a difference between natalizumab-treated patients and controls. JC viral load was higher in CD34(+) cells and in monocytes compared to other subpopulations. ICS was more sensitive than ELISpot. JCV-specific T-cell responses, mediated by both CD4(+) and CD8(+) T lymphocytes, were detected more frequently after in vitro stimulation. JCV-specific CD4(+) T cells were detected ex vivo more frequently in MS patients with JCV DNA in CD34(+) (p = 0.05) and B cells (p = 0.03). INTERPRETATION: Asymptomatic JCV reactivation may occur in CSF of natalizumab-treated MS patients. JCV DNA load is higher in circulating CD34(+) cells and monocytes compared to other mononuclear cells, and JCV in blood might trigger a JCV-specific CD4(+) T-cell response. JCV-specific cellular immune response is highly prevalent in all JCV-seropositive MS patients, regardless of treatment.
OBJECTIVE: To determine the prevalence of JC virus (JCV) reactivation and JCV-specific cellular immune response during prolonged natalizumab treatment for multiple sclerosis (MS). METHODS: We enrolled 43 JCV-seropositive MSpatients, including 32 on natalizumab monotherapy >18 months, 6 on interferon β-1a monotherapy >36 months, and 5 untreated controls. We performed quantitative real-time polymerase chain reaction in cerebrospinal fluid (CSF), blood, and urine for JCV DNA, and we determined JCV-specific T-cell responses using enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine staining (ICS) assays, ex vivo and after in vitro stimulation with JCV peptides. RESULTS:JCV DNA was detected in the CSF of 2 of 27 (7.4%) natalizumab-treated MSpatients who had no symptoms or magnetic resonance imaging-detected lesions consistent with progressive multifocal leukoencephalopathy. JCV DNA was detected in blood of 12 of 43 (27.9%) and in urine of 11 of 43 (25.6%) subjects without a difference between natalizumab-treated patients and controls. JC viral load was higher in CD34(+) cells and in monocytes compared to other subpopulations. ICS was more sensitive than ELISpot. JCV-specific T-cell responses, mediated by both CD4(+) and CD8(+) T lymphocytes, were detected more frequently after in vitro stimulation. JCV-specific CD4(+) T cells were detected ex vivo more frequently in MSpatients with JCV DNA in CD34(+) (p = 0.05) and B cells (p = 0.03). INTERPRETATION: Asymptomatic JCV reactivation may occur in CSF of natalizumab-treated MSpatients. JCV DNA load is higher in circulating CD34(+) cells and monocytes compared to other mononuclear cells, and JCV in blood might trigger a JCV-specific CD4(+) T-cell response. JCV-specific cellular immune response is highly prevalent in all JCV-seropositive MSpatients, regardless of treatment.
Authors: V Dubois; H Dutronc; M E Lafon; V Poinsot; J L Pellegrin; J M Ragnaud; A M Ferrer; H J Fleury Journal: J Clin Microbiol Date: 1997-09 Impact factor: 5.948
Authors: M E Lafon; H Dutronc; V Dubois; I Pellegrin; P Barbeau; J M Ragnaud; J L Pellegrin; H J Fleury Journal: J Infect Dis Date: 1998-06 Impact factor: 5.226
Authors: R Caldarelli-Stefano; L Vago; E Omodeo-Zorini; M Mediati; L Losciale; M Nebuloni; G Costanzi; P Ferrante Journal: J Neurovirol Date: 1999-04 Impact factor: 2.643
Authors: Caroline Ryschkewitsch; Peter Jensen; Jean Hou; Gary Fahle; Steven Fischer; Eugene O Major Journal: J Virol Methods Date: 2004-11 Impact factor: 2.014
Authors: Maria Inmaculada Dominguez-Mozo; Marta Garcia-Montojo; Virginia De Las Heras; Angel Garcia-Martinez; Ana María Arias-Leal; Ignacio Casanova; Rafael Arroyo; Roberto Alvarez-Lafuente Journal: J Neuroimmune Pharmacol Date: 2013-08-25 Impact factor: 4.147
Authors: Emanuelle Bellaguarda; Kian Keyashian; Joel Pekow; David T Rubin; Russell D Cohen; Atsushi Sakuraba Journal: Clin Gastroenterol Hepatol Date: 2015-05-19 Impact factor: 11.382
Authors: Sarah M Corbridge; Richard C Rice; Linda A Bean; Christian Wüthrich; Xin Dang; Daniel A Nicholson; Igor J Koralnik Journal: J Neurovirol Date: 2019-04-25 Impact factor: 2.643
Authors: Miriam Mattoscio; Richard Nicholas; Maria P Sormani; Omar Malik; Jean S Lee; Adam D Waldman; Francesco Dazzi; Paolo A Muraro Journal: Neurology Date: 2015-03-11 Impact factor: 9.910
Authors: Christa S Zerbe; Beatriz E Marciano; Rohit K Katial; Carah B Santos; Nick Adamo; Amy P Hsu; Mary E Hanks; Dirk N Darnell; Martha M Quezado; Cathleen Frein; Lisa A Barnhart; Victoria L Anderson; Gulbu Uzel; Alexandra F Freeman; Andrea Lisco; Avindra Nath; Eugene O Major; Elizabeth P Sampaio; Steven M Holland Journal: Clin Infect Dis Date: 2016-01-06 Impact factor: 9.079